Clear cell carcinoma of kidney
Conditions
Interventions
Gold Standard:Pathological diagnosis
Index test:Diagnostic efficacy of PET-CT imaging agent
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.between 18 and 80 years old, regardless of gender; 2.Radiologically suspected patients with renal cell carcinoma; 3.Radiographic findings showed suspicious lymph node or distant metastasis; 4.Informed consent must be signed in person by the subject or his legal guardian or caregiver; 5.Willing and able to cooperate with all projects of this study;
Exclusion criteria
Exclusion criteria: 1.Patients receiving antitumor therapy before PET/CT scan; 2.Have other serious neurological disorders, or gastrointestinal, cardiovascular, liver, kidney, blood, respiratory, immune deficiencies, and other serious disorders; 3.Candidate subjects are contraindicated for PET/CT scanning;This includes, but is not limited to, failure to effectively control elevated blood sugar; Pregnant, lactating or lactating women; Unable to receive repeated intravenous injections; on medications .Patients with possible allergies to their components (including a history of severe allergies or anaphylaxis, especially the drugs being tested allergies); Constrictophobia 4.Within the past year, in addition to participating in the radiation exposure expected for this clinical study, you have participated in other research protocols or clinical care that resulted in radiation exposure exceeding the effective dose of 50 mSv; 5.Candidate subjects have undergone major surgery within the last 3 months; Received an experimental drug or device within 1 month (whose efficacy or safety is unclear); 6.Candidate subjects have any clinical condition that the study sponsor believes may cause or is potentially harmful;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| [18F] Sensitivity of RCCB6 in the diagnosis of renal cancer;[18F] Jorden index of RCCB6 in the diagnosis of renal cancer;[18F] Specificity of RCCB6 in the diagnosis of renal cancer; | — |
Countries
China
Contacts
Public ContactZhai Wei
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed